Finke J H, Rayman P, Hart L, Alexander J P, Edinger M G, Tubbs R R, Klein E, Tuason L, Bukowski R M
Department of Immunology, Cleveland Clinic Foundation, OH 44195.
J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):91-104. doi: 10.1097/00002371-199402000-00002.
The detection of T cells with specificity for human renal cell carcinoma (RCC) has been difficult to document. In an attempt to improve our identification of RCC-reactive T cells, tumor-infiltrating lymphocytes (TIL) were expanded in interleukin-2/interleukin-4 (IL-2/IL-4) and then separated into CD4+ and CD8+ subsets using antibody-coated biomagnetic beads. TIL grown in IL-2/IL-4 expanded to greater numbers than TIL grown in IL-2 alone. From 16 patients in whom subset separation was performed, three CD4+ and three CD8+ TIL consistently had specificity for RCC that was detected by cytotoxicity, proliferation, or interferon-gamma (IFN-gamma) production. Four of the six lines were derived from the IL-2/IL-4 cultures. Two CD8+ TIL lines displayed specific lytic activity, lysing the autologous tumor but not allogeneic RCC or nonrenal tumors. Moreover, the lytic activity of these lines was blocked by anti-CD3 antibody, suggesting that tumor recognition was through the TCR/CD3 complex. Two additional TIL lines showed preferential lysis of RCC because they were cytotoxic for autologous tumor and one or more allogeneic RCC but not other tumor types. Two nonlytic CD4+ lines as well as the two CD8+ lines that were specifically lytic also produced IFN-gamma in response to the autologous tumor but not allogeneic RCC. Although these TIL lines produce IFN-gamma when stimulated with tumor alone, the addition of 5 U/ml of IL-2 significantly enhanced IFN-gamma secretion. The four TIL lines that showed specificity for RCC in terms of IFN-gamma production also had enhanced proliferation to the autologous RCC plus IL-2 but not to multiple allogeneic RCC plus IL-2. These studies demonstrate that TIL from RCC patients contain both CD4+ and CD8+ T cells that have specificity for RCC. In addition to cytotoxicity, specificity to RCC can be defined by IFN-gamma production and proliferation.
一直以来,很难证实存在对人类肾细胞癌(RCC)具有特异性的T细胞。为了改进我们对RCC反应性T细胞的识别,将肿瘤浸润淋巴细胞(TIL)在白细胞介素-2/白细胞介素-4(IL-2/IL-4)中进行扩增,然后使用抗体包被的生物磁珠将其分离为CD4 +和CD8 +亚群。在IL-2/IL-4中生长的TIL比仅在IL-2中生长的TIL扩增到更多数量。在进行亚群分离的16例患者中,三个CD4 +和三个CD8 + TIL始终对RCC具有特异性,可通过细胞毒性、增殖或干扰素-γ(IFN-γ)产生来检测。六个细胞系中的四个来自IL-2/IL-4培养物。两个CD8 + TIL细胞系表现出特异性溶解活性,可溶解自体肿瘤,但不溶解同种异体RCC或非肾肿瘤。此外,这些细胞系的溶解活性被抗CD3抗体阻断,表明肿瘤识别是通过TCR/CD3复合物进行的。另外两个TIL细胞系显示出对RCC的优先溶解,因为它们对自体肿瘤和一种或多种同种异体RCC具有细胞毒性,但对其他肿瘤类型没有细胞毒性。两个非溶解型CD4 +细胞系以及两个具有特异性溶解作用的CD8 +细胞系在受到自体肿瘤刺激时也产生IFN-γ,但对同种异体RCC不产生IFN-γ。尽管这些TIL细胞系仅在受到肿瘤刺激时产生IFN-γ,但添加5 U/ml的IL-2可显著增强IFN-γ的分泌。就IFN-γ产生而言,对RCC具有特异性的四个TIL细胞系对自体RCC加IL-2的增殖也增强,但对多种同种异体RCC加IL-2的增殖没有增强。这些研究表明,来自RCC患者的TIL包含对RCC具有特异性的CD四+和CD8 + T细胞。除细胞毒性外,对RCC的特异性还可通过IFN-γ产生和增殖来定义。